2010
DOI: 10.4172/1948-5956.1000022
|View full text |Cite
|
Sign up to set email alerts
|

Endocan as a Biomarker of Endothelial Dysfunction in Cancer

Abstract: Endocan also called endothelial cell-specific-molecule-1 is a product of endothelial cells, highly regulated by vascular endothelial growth factor and expressed during the switch between dormant to fast-growing angiogenic tumors. No other molecule is currently known to be a read out of endothelial activation and dysfunction in tumor progression. We here reviewed the present knowledge about endocan that present clinical value as a tissue-and blood-based prognostic and potentially as a companion biomarker in can… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
10
0

Year Published

2011
2011
2020
2020

Publication Types

Select...
4
4

Relationship

0
8

Authors

Journals

citations
Cited by 27 publications
(10 citation statements)
references
References 20 publications
0
10
0
Order By: Relevance
“…The release of Endocan by cultured endothelial cells has been largely described to be strongly upregulated in presence of proangiogenic molecules such as VEGF, FGF-2, and VEGF-C that are critical mediators involved in angiogenesis (i.e., formation of blood vessel), lymphangiogenesis (i.e., formation of lymphatic vessel), and cancer progression (spreading and metastasis) [23, 28, 35, 36, 39, 66]. In addition, Endocan has been shown to directly promote the mitogenic and migratory activities of VEGF-A and -C on cultured endothelial cells [66].…”
Section: Vascular Endocan As a Biomarker Of Neoangiogenesis In Cancermentioning
confidence: 99%
See 2 more Smart Citations
“…The release of Endocan by cultured endothelial cells has been largely described to be strongly upregulated in presence of proangiogenic molecules such as VEGF, FGF-2, and VEGF-C that are critical mediators involved in angiogenesis (i.e., formation of blood vessel), lymphangiogenesis (i.e., formation of lymphatic vessel), and cancer progression (spreading and metastasis) [23, 28, 35, 36, 39, 66]. In addition, Endocan has been shown to directly promote the mitogenic and migratory activities of VEGF-A and -C on cultured endothelial cells [66].…”
Section: Vascular Endocan As a Biomarker Of Neoangiogenesis In Cancermentioning
confidence: 99%
“…Since then, Endocan has rapidly emerged as a very distinctive PG, in many aspects: (i) Endocan is the one of very few circulating PG sensu stricto , (ii) in contrast with most ECM PGs, which are usually large, modular proteins that harbor several GAG chains, Endocan comprises a relatively small polypeptide associated to one single polysaccharide chain, and (iii) characterization of Endocan DS chain revealed uncommon structural features and saccharide composition [22]. Interestingly, increasing experimental evidence has reported that Endocan is overexpressed in cancer, sepsis, obesity, or inflammatory conditions [20, 21, 2328]. Furthermore, blood levels of freely circulating PG have been associated with poor prognosis in several types of cancers (reviewed in [28]).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…It is thought that this aberrant vessel plexus gives immune protection to developing malignant cells by preventing egress and local activity of natural killer (NK) cells [13,14]. Fibroblasts originated from type-3 EMT are designated as “cancer-associated fibroblasts” [15].…”
Section: Letter To the Editormentioning
confidence: 99%
“…Recently, endocan was reported to dose-dependently inhibit migration in transmigration endothelial assays of NK cells that reside naturally in the vasculature. [10] M A N U S C R I P T…”
Section: Introductionmentioning
confidence: 99%